Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-20260425-224724",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "codex_task_runner",
  "action": "synthesize",
  "content": "Synthesizer consensus: The Skeptic's causal-direction warning is decisive, but the Theorist and Expert identified tractable experiments. The debate therefore promotes three testable hypotheses and recommends moving the gap to investigating.\n\n```json\n{\n  \"gap_id\": \"gap-20260425-224724\",\n  \"synthesis_summary\": \"The debate supports investigation rather than resolution. The strongest path is a longitudinal perturbation design that separates causal drivers from adaptive or downstream responses.\",\n  \"ranked_hypotheses\": [\n    {\n      \"hypothesis_id\": \"h-gap-2f2e5b80-m1\",\n      \"title\": \"TLR4 priming is the actionable driver in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration th\",\n      \"description\": \"The gap can be tested by treating TLR4 priming as an upstream driver rather than a passive correlate. If true, perturbing butyrate-restoring consortia should shift fecal butyrate before downstream neurodegeneration markers change.\",\n      \"target_gene\": \"TLR4 priming\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.74,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.76,\n        \"feasibility\": 0.68,\n        \"therapeutic_potential\": 0.82,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.75\n    },\n    {\n      \"hypothesis_id\": \"h-gap-2f2e5b80-m2\",\n      \"title\": \"plasma LPS-binding protein separates causal from compensatory states in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegenerat\",\n      \"description\": \"A longitudinal biomarker panel centered on plasma LPS-binding protein can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma LPS-binding protein before and after TLR4 antagonism in stratified models.\",\n      \"target_gene\": \"plasma LPS-binding protein\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.69,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.78,\n        \"therapeutic_potential\": 0.76,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.7375\n    },\n    {\n      \"hypothesis_id\": \"h-gap-2f2e5b80-m3\",\n      \"title\": \"microglial inflammasome tone defines the therapeutic window for: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegener\",\n      \"description\": \"The same signal may be beneficial early and damaging late. Testing microglial inflammasome tone with dietary fiber challenge should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.\",\n      \"target_gene\": \"microglial inflammasome tone\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.66,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.79,\n        \"feasibility\": 0.64,\n        \"therapeutic_potential\": 0.8,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.7225\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"gap-20260425-224724\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-2f2e5b80-m1\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-2f2e5b80-m1\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"TLR4 priming\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    },\n    {\n      \"source_id\": \"gap-20260425-224724\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-2f2e5b80-m2\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-2f2e5b80-m2\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"SCFA depletion\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    },\n    {\n      \"source_id\": \"gap-20260425-224724\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-2f2e5b80-m3\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-2f2e5b80-m3\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"microglial inflammasome tone\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    }\n  ],\n  \"recommended_next_steps\": [\n    \"Prioritize longitudinal samples that establish temporal order.\",\n    \"Run perturbational validation in a model where the proposed mechanism is active.\",\n    \"Pre-register subgroup definitions before comparing therapeutic response.\"\n  ],\n  \"verdict\": \"investigating\"\n}\n```",
  "hypotheses_referenced": "[\"h-gap-2f2e5b80-m1\", \"h-gap-2f2e5b80-m2\", \"h-gap-2f2e5b80-m3\"]",
  "evidence_cited": "[]",
  "tokens_used": "1220",
  "persona_id": "persona-synthesizer"
}